Insulin infusion therapy

Bibliography

• Albisser AM, McAdam KP, Perlman K, et al. Unanticipated amyloidosis in dogs infused with insulin. Diabetes 1983: 32(12): 1092–101
   PubMed Web of Science ®Google Scholar
• Boulton AJ, Drury J, Clarke B, et al. Continuous subcutaneous insulin infusion in the management of painful diabetic neuropathy. Diabetes Care 1982: 5(4): 386–90
   PubMed Web of Science ®Google Scholar
• Boulton AJ, Knight G, Drury J, et al. Diabetic ketoacidosis associated with outpatient treatment using continuous subcutaneous insulin infusion. Postgrad Med J 1983: 59(693): 483–9
   PubMedGoogle Scholar
• Brownlee M, Vlassara H, Cerami A, et al. Association of insulin pump therapy with raised serum amyloid A in type I diabetes mellitus. Lancet 1984: 1(8374): 411–3
   PubMed Web of Science ®Google Scholar
• Chiasson JL, Ducros P, Poliquin-Hamet M, et al. Continuous subcutaneous insulin infusion (Mill-Hill infuser) versus multiple injections (Medi-Jector) in the treatment of insulin-dependent diabetes mellitus and the effect of metabolic control on microangiopathy. Diabetes Care 1984: 7(4): 331–7
   PubMed Web of Science ®Google Scholar
• Dahl-Jorgensen D, Brinchmann-Hansen O, Hansen KF, et al. Transient deterioration of retinopathy when multiple insulin injection therapy and CSII is started in IDDM patients. Diabetes 1984: 33(Suppl 1): 4A(14)
   Google Scholar
• Dimitriadis GD, Gerich JE. Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care 1983: 6(4): 374–7
   PubMed Web of Science ®Google Scholar
• Falko JM, O'Dorisio TM, Cataland S. Improvement of high-density lipoprotein-cholesterol levels. Ambulatory type I diabetics treated with the subcutaneous insulin pump. JAMA 1982: 247(1): 37–9
   PubMed Web of Science ®Google Scholar
• Geffner ME, Frank HJ, Kaplan SA, et al. Early-morning hyperglycemia in diabetic individuals treated with continuous subcutaneous insulin infusion. Diabetes Care 1983: 6(2): 135–9
   PubMed Web of Science ®Google Scholar
• Koivisto VA, Teppo AM, Maury CP, et al. No evidence of amyloidosis in type I diabetics treated with continuous subcutaneous insulin infusion. Diabetes 1983: 32(1): 88–90
   PubMed Web of Science ®Google Scholar
• Kroc Collaborative Study Group. Blood glucose control and the evolution of diabetic retinopathy and albuminuria: a preliminary multicenter trial. N Engl J Med 1984: 311(6): 365–72
   PubMed Web of Science ®Google Scholar
• Krzentowski G, Sheen A, Castillo M, et al. A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion. 1. Metabolic and hormonal consequences and scheme for a prompt return to adequate control. Diabetologia 1983: 24(5): 314–8
   PubMed Web of Science ®Google Scholar
• Lacy PE. Experimental immuno-alteration. World J Surg 1984: 8(2): 198–203
   PubMed Web of Science ®Google Scholar
• Pickup JC, Keen H, Parsons JA, et al. Continuous subcutaneous insulin infusion: an approach to achieving normoglycemia. Br Med J 1978: 1(6107): 204–7
   PubMed Web of Science ®Google Scholar
• Pietri A, Dunn FL, Raskin P. The effect of improved diabetic control on plasma lipid and lipoprotein levels: a comparison of conventional therapy and continuous subcutaneous insulin infusion. Diabetes 1980: 29(12): 1001–5
   PubMed Web of Science ®Google Scholar
• Pietri A, Ehle AL, Raskin P. Changes in nerve conduction velocity after six weeks of glucoregulation with portable insulin infusion pumps. Diabetes 1980: 29(8): 668–71
   PubMed Web of Science ®Google Scholar
• Polonsky K, Bergenstal R, Pons G, et al. Relation of counterregulatory responses to hypoglycemia in type I diabetics. N Engl J Med 1982: 307(18): 1106–12
   PubMed Web of Science ®Google Scholar
• Raskin P, Pietri A, Unger R. Changes in glucagon levels after four to five weeks of glucoregulation by portable insulin infusion pumps. Diabetes 1979: 28: (11)1033–5
   PubMed Web of Science ®Google Scholar
• Raskin P, Pietri AO, Unger R, et al. The effect of diabetic control on the width of skeletal-muscle capillary basement membrane in patients with type I diabetes mellitus. N Engl J Med 1983: 309(25): 1546–50
   PubMed Web of Science ®Google Scholar
• Schmidt MI, Hadji-Georgopoulos A, Rendell M, et al. The dawn phenomenon, an early morning glucose rise: implications for diabetic intraday blood glucose variation. Diabetes Care 1981: 4(6): 579–85
   PubMed Web of Science ®Google Scholar
• Service FJ, Dyck PJ, Daube JR, et al. Randomized clinical trial of the effect of glucose control from CSII on peripheral nerve function in IDDM. Diabetes 1983: 32(Suppl 1): 10A(40)
   Google Scholar
• Shichiri M, Kawamori R, Yamasaki Y, et al. Feasibility of the wearable artificial endocrine pancreas with a needle-type glucose sensor in clinical application. Diabetes 1983: 32(Suppl 1): 36A(144)
   Google Scholar
• Shichiri M, Kawamori R, Yamasaki Y, et al. Essentiality of closed-loop control system—day-by-day variation in glycemic response. Diabetes 1984: 33(Suppl 1): 74A(293)
   PubMedGoogle Scholar
• Siperstein MD, Foster DW, Knowles HC, et al. Control of blood glucose and diabetic vascular disease. (Editorial) N Engl J Med 1977: 296(18): 1060–3
   PubMed Web of Science ®Google Scholar
• Sosenko JM, Miettinen OS, Williamson JR, et al. Muscle capillary basement-membrane thickness and long-term glycemia in type I diabetes mellitus. N Engl J Med 1984: 311(11): 694–8
   PubMed Web of Science ®Google Scholar
• Störkel S, Schneider HM, Müntefering H, et al. latrogenic, insulin-dependent, local amyloidosis. Lab Invest 1983: 48(1): 53–9
   PubMedGoogle Scholar
• Sutherland DE, Chinn PL, Goetz FC, et al. Minnesota experience with 85 pancreas transplants between 1978 and 1983. World J Surg 1984: 8(2): 244–52
   PubMed Web of Science ®Google Scholar
• Tamborlane WV, Puklin JE, Bergman M, et al. Long-term improvement of metabolic control with the insulin pump does not reverse diabetic microangiopathy. Diabetes Care 1982: 5(Suppl 1): 58–64
   PubMed Web of Science ®Google Scholar
• Tamborlane WV, Sherwin RS, Genel M, et al. Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable insulin infusion pump. N Engl J Med 1979: 300(11): 573–8
   PubMed Web of Science ®Google Scholar
• Tamborlane WV, Sherwin RS, Genel M, et al. Restoration of normal lipid and aminoacid metabolism in diabetic patients treated with a portable insulin-infusion pump. Lancet 1979: 1(8129): 1258–61
   PubMed Web of Science ®Google Scholar
• Tamborlane WV, Sherwin RS, Koivisto V, et al. Normalization of the growth hormone and catecholamine response to exercise in juvenile-onset diabetic subjects treated with a portable insulin infusion pump. Diabetes 1979: 28(8): 785–8
   PubMed Web of Science ®Google Scholar
• Teutsch SM, Herman WH, Dwyer DM, et al. Mortality among diabetic patients using continuous subcutaneous insulin-infusion pumps. N Engl J Med 1984: 310(6): 361–8
   PubMed Web of Science ®Google Scholar
• White NH, Skor DA, Cryer PE, et al. Identification of type I diabetic patients at increased risk for hypoglycemia during intensive therapy. N Engl J Med 1983: 308(9): 485–91
   PubMed Web of Science ®Google Scholar
• White NH, Skor DA, Santiago JV. Dawn phenomenon and intensified therapy. Diabetes Care 1983: 6(5): 525
   PubMed Web of Science ®Google Scholar